• 제목/요약/키워드: Phosphodiesterase 4 inhibitor

검색결과 49건 처리시간 0.027초

Rolipram, a Phosphodiesterase 4 Inhibitor, Stimulates Osteoclast Formation by Inducing TRANCE Expression in Mouse Calvarial Cells

  • Cho, Eun-Sook;Yu, Ja-Heon;Kim, Mi-Sun;Yim, Mi-Jung
    • Archives of Pharmacal Research
    • /
    • 제27권12호
    • /
    • pp.1258-1262
    • /
    • 2004
  • Phosphodiesterase (PDE) 4 is an enzyme that degrades intracellular cAMP. In the present study, the effect of rolipram, a specific phosphodiesterase (PDE) 4 inhibitor, on osteoclast formation was investigated. Rolipram induced osteoclast formation in cocultures of mouse bone marrow cells and calvarial osteoblasts. This activity was not observed in the absence of calvarial osteoblasts, suggesting that calvarial osteoblasts are likely target cells of rolipram. Osteoclast formation by rolipram was completely blocked by the addition of osteoprotegerin (OPG), a soluble decoy receptor for the osteoclast differentiation factor, TNF-related activation-induced cytokine (TRANCE, identical to RANKL, ODF, and OPGL). Northern blot analysis revealed the effect of rolipram to be associated with the increased expression of TRANCE mRNA in mouse calvarial osteoblasts. Collectively, these data indicate that PDE4 inhibitor up-regulates the TRANCE mRNA expression in osteoblasts, which in turn controls osteoclast formation.

The Effect of Phosphodiesterase-4-Specific Inhibitor in the Rat Model of Spinal Nerve Ligation

  • Kim, Sung-Hoon;Park, Bit-Na-Ri;Kim, Seok-Won
    • Journal of Korean Neurosurgical Society
    • /
    • 제50권2호
    • /
    • pp.109-113
    • /
    • 2011
  • Objective : Peripheral neuropathy is characterized by hyperalgesia, spontaneous burning pain, and allodynia. The purpose of this study was to investigate the effect of rolipram, a phosphodiesterase-4-specific inhibitor, in a segmental spinal nerve ligation model in rats. Methods : Both the L5 and L6 spinal nerves of the left side of the rats were ligated. Phosphodiesterase-4 inhibitor (rolipram) and saline (vehicle) were administered intraperitoneally. We measured mechanical allodynia using von Frey filaments and a nerve conduction study. Results : The mechanical allodynia, which began to manifest on the first day, peaked within 2 days. Multiple intraperitoneal injections of rolipram ameliorated the mechanical allodynia. Furthermore, an intraperitoneal administration of rolipram improved the development of pain behavior and nerve conduction velocity. Conclusion : This study suggests that the phosphodiesterase-4 inhibitor, rolipram, alleviates mechanical allodynia induced by segmental spinal nerve ligation in rats. This finding may have clinical implications.

Phosphodiesterase 4와 7에 대한 억제 기전을 갖는 아토피 억제 물질의 탐색 (Screening of Anti-atopic Herbs Having Phosphodiesterase 4 and 7 Inhibition)

  • 윤원호;이경호
    • 생약학회지
    • /
    • 제45권3호
    • /
    • pp.268-274
    • /
    • 2014
  • The aim of this study is to explore the potent phosphodiesterase 4 and 7 inhibitor from various herbal medicines for atopy treatment. In this study, 51 kinds of each herbal medicine, which were extracted with ethanol, was carried out the screening of PDE 4 and 7 inhibition using enzyme inhibitory assay. Of these, 8 species of herbal medicines, Rubus coreanus, Duchesnea chrysantha, Alisma orientale, Rehmannia glutinosa, Angelica dahurica, Thuja orientalis, Astragalus membranaceus and Perilla frutescens were screened as potential inhibitor against PDE 4 and 7. Among 8 species, Duchesnea chrysantha showed poteinial anti-atopic effect on DNCB-induced atopic model. Duchesnea chrysantha extract decreased serum IgE and histamine release significantly.

Effects of a New Selective Phosphodiesterase Type 5 Inhibitor, KJH-1002, on the Relaxation of Rabbit Corpus Cavernosum Tissue

  • Cho, Eun-Young;Chung, Sung-Hyun;Kim, Joong-Hyup;Kim, Dong-Hyun;Jin, Cang-Bae
    • Biomolecules & Therapeutics
    • /
    • 제11권4호
    • /
    • pp.232-237
    • /
    • 2003
  • The present study examined functional effects of a new selective phosphodiesterase type 5 inhibitor, 1-[4-ethoxy-3-(6,7-dihydro-1-methyl-7-thioxo-3-propyl-1H-pyrazolo[ 4,3]pyrimidin-5-yl)phenylsulphonyl]-4-methyl piperazine (KJH-1002), in the isolated rabbit corpus cavernosum (RCC). Relaxing effects of KJH-1002 were also compared with those of sildenafil, which is currently used as an oral therapy for penile erectile dysfunction. In the isolated RCC precontracted with phenylephrine, both KJH-1002 and sildenafil in the concentration range of 1 to 1000 nM, produced a comparable potentiation of the electical field stimulation-induced relaxation in a concentration-dependent manner. In the sodium nitroprusside (SNP)-induced relaxation, the $IC_{50}$/ values, concentrations of SNP required to produce a 50% relaxation of the phenylephrine-induced contraction, were significantly decreased to the similar extent by treatments with KJH-1002 and sildenafil. The results suggest that a new selective phosphodiesterase type 5 inhibitor, KJH-1002, has an augmentative effect on penile erection comparable to that of sildenafil and can be useful for the treatment of erectile dysfunction.

Type IV phosphodiesterase inhibitor(CJ-10882)의 개에 대한 2주간 경구반복투여 독성시험 (Toxicity Study of CJ-10882, a Type IV Phosphodiesterase Inhibitor: 2 Weeks Repeated Oral Administration in Beagle Dogs)

  • 한정희;배주현;김종춘;김달현;이근호;송석범;차신우
    • Biomolecules & Therapeutics
    • /
    • 제10권2호
    • /
    • pp.117-123
    • /
    • 2002
  • CJ-10882, (E)-[(3-Cyclopentyloxy-4-methoxyphenyl)methylene]hydrazine-carboxamide, is a newly developed type IV phosphodiesterase isozyme (PDE IV) inhibitor. To investigate the subacute toxic effects of CJ-10882, it was administered to both male and female dogs at 0, 25, 50, 100 or 200 mg/kg/day orally for up to 2 weeks. During the test period, clinical signs, mortality, body weight, food consumption, ophthalmoscopy, urinalysis, hematology, serum biochemistry, gross finding, organ weight, and histopathology were evacuated. Several clinical signs were observed in treated dogs at above 25 mg/kg, including salivation and vomiting. A reduction in the body weight was observed in both sexes at above 50 mg/kg. There were no treatment-related effects on mortality, ophthalmoscopy, urinalysis, hematology, sect biochemistry, necropsy findings, and histopathology in any treatment group. The results of this study demonstrate that CJ-10882, a selective Inhibitor of the type IV class of PDE, may cause effects on gastrointestinal tract and salivary glands. Therefore, these organs should be closely examined in studies with other PDE IV inhibitors.

미생물 효소에 의한 핵산 및 그의 관련물질의 분해에 관한 연구 (Studies on Degradation of Nucleic acid and Related Compounds by Microbial Enzymes)

  • 김상순
    • Applied Biological Chemistry
    • /
    • 제13권2호
    • /
    • pp.111-129
    • /
    • 1970
  • 핵산 및 그 관련물질 연구의 일환으로서 미생물 효소에 의하여 핵산을 분해하여 5'-mononucleotides 생성을 목적으로 미생물에서 5'-phosphodiesterase 생성균주를 얻기위하여 전국 각지 76개 지역에서 논, 밭, 산, 하천의 토양 그리고 퇴비, 누룩, 메주 등 시료 210종을 수집하였다. 이 수집 시료로 부터 dilution pour plate method 로서 Aspergillus속 240주, Penicillium속 232주, Neurospora속, 19주, Monascus속 16주, 그리고 Streptomyces속 265주로 총 758주를 순수 분리하였다. 분리된 모든 균주에 대하여 RNA-depolymerase 균의 crude enzyme 중에는 5'-AMP deaminase가 공존하고 있으므로 효소반응 중에 RNA 가 5'-mononucleotide로 분해 축적하는 동안에 5'-AMP의 adenine의 6위치에 붙은 $NH_2$기를 탈아미노하여 hypoxanthine으로 하기 때문에 5'-IMP 로 되는 것이라 생각된다. 분리 동정 된 Penicillium citreo-viride PO 2-11 strain과 Streptomyces aureus SOA 4-21 strain 이 생성한 5'-phosphodiesterase 로서 RNA를 효소 분해하여 5'-mononucleotide 의 정량한 결과는 Table 10과 같다. productivities를 1차 screening 하고 5'-phosphodiesterase productivities로서 2차 screening 하여 우수균주를 얻고 동정하였다. 우수균주의 5'-phosphodiesterase productivity에 대하여 배양상의 optimum condition을 검토하고 5'-phosphodiesterse activity에 미치는 여러 화합물의 영향과 효소반응의 최적 조건을 구명하였다. 우수균주가 생성한 5'-phosphodiesterase에 의하여 RNA 분해로 반응 최종 산물을 ion exchange column chromatography법으로 정량하고 최종 분해 산물엔 5'-mononucleotide를 paper chromatography, thinlayer chromatography, UV-absorption spectra, carbazole reaction 및 Schiff's reaction 등으로 동정한 결과는 다음과 같다. [1] 5'-phosphodiesterase productivity가 가장 우수한 두 균주를 선정하였고 이들은 토양에서 분리 되었으며 선정된 푸른 곰팡이는 Penicillium citreoviride PO 2-11로 동정되었고 방사선균은 Streptomyces aureus SOA 4-21로 동정되었다. [2] 분리 선정 된 Penicillium citreo-viride PO 2-11 strain은 배양상의 optimum condition 이 pH 5.0이고 temperature는 $30^{\circ}C$이었고 이 균이 생성한 5'-phosphodiesterase의 효소 반응상의 optimum condition 이 pH 4.2이고 temperature는 $60^{\circ}C$이었다. 그리고 5'-phosphodiesterase 생성에서 최적 탄소원은 sucrose이고 질소원은 $NH_4NO_3$이고 corn steep liquor나 혹은 yeast extract를 각각 0.01%씩 첨가한 구는 첨가하지 않은 control 구보다 20%의 5'-phosphodiesterase 생성 증가를 나타 내었다. 이 균이 생성한 5'-phosphodiestrase는 $Mg^{++},\;Ca^{++},\;Zn^{++},\;Mn^{++}$ 등 금속이온은 activator이고 EDTA, citrate, $Cu^{++},\;Co^{++}$ 등은 inhibitor 임을 알았다. 이 균이 생성한 5'-phosphodiesterase는 RNA를 분해하여 분해율 65.81%이었고 5'-AMP, 5'-GMP, 5'-UMP 및 5'-CMP를 생성하며 이때 축적되는 5'-mononucleotides중 5'-GMP 만이 정미성이 있음을 알았고 이균은 5'-AMP deamaminase가 없음을 확인하였다. 이 균의 효소에 의하여 RNA에서 정미성 5'-GMP 186.7 mg/RNA(g)를 생산할수 있음을 알았다. [3] 분리 선정된 Streptomyces aureus SOA 4-21 strain은 배양상의 optimum condition이 pH 7.0이고 temperature는 $28^{\circ}C$이었고 이 균이 생성한 5'-phosphodiesterase의 효소반응상의 optimum condition이 pH 7.3이고 temperature는 $50^{\circ}C$이었다. 그리고 5'-phosphodiesterase 생성에서 최적탄소원은 glucose이고 질소원은 asparagine이고 yeast extract 0.01%첨가구가 control 구보다 40%의 5'-phosphodiesterase 생성증가를 나타내었다. 이 균이 생성한 5'-phosphodiesterase는 $Ca^{++},\;Zn^{++},\;Mn^{++}$ 등 금속이온은 activator 이고 citrate, EDTA, $Cu^{++}$ 등은 inhibitor 임을 알았다. 또한 이 균은 5'-phosphodiesterase 뿐만 아니라 5'-AMP deaminase도 생성함을 확인하였다. 그러므로 RNA 분해율은 63.58% 이었고 RNA를 분해하여 5'-AMP, 5'-CMP, 5'-GMP 및 5'-UMP로 축적시키고 RNA가 효소 분해됨과 동시에 5'-AMP deaminase도 작용하며 생성된 5'-AMP 의 60% 상당을 5'-IMP로 전환시키는 특성이 있어서 정미성 5'-mononucleotide 생성이 전자의 균보다 두드러지게 증가함을 밝혔다. 이 균에 의하여 RNA에서 정미성 5'-IMP 171.8 mg/RNA(g) 및 5'-GMP 148.2 mg/RNA(g)생산할 수 있어 정미성 5'-mononucleotide 320mg/RNA(g)를 생산할 수 있음을 알았다.

  • PDF

Subacute toxicities and toxicokinetics of CJ-10882, a type IV phosphodiesterase inhibitor, after 4-week repeated oral administration in dogs

  • Junghee Han;Cha, Shin-Woo;Im, Doo-Hyun;Chung, Moon-Koo
    • 한국독성학회:학술대회논문집
    • /
    • 한국독성학회 2003년도 춘계학술대회 논문집
    • /
    • pp.43-44
    • /
    • 2003
  • The subacute toxicity and toxicokinetics of a type IV phosphodiesterase inhibitor, CJ-10882, were evaluated after single (on the 1st day) and 4-week (on the 27th day) oral administration of the drug, in doses of 0 (to serve as a control), 2, 10 and 50 mg/kg/d, to male and female dogs (n = 3 for male and female dogs for each dose). During the test period, clinical signs, mortality, body weight, food consumption, ophthalmoscopy, urinalysis, hematology, serum biochemistry, gross findings, organ weight and histopathology were examined.(omitted)

  • PDF

LPS의 파골세포 분화 유도에 미치는 PDE4 저해제의 증강효과 (The Effect of PDE4 Inhibitor on LPS-Induced Osteoclastogenesis)

  • 노아롱새미;천링;임미정
    • 약학회지
    • /
    • 제52권1호
    • /
    • pp.43-47
    • /
    • 2008
  • To determine the regulatory roles of PDE4 inhibitor on LPS-induced osteoclastogenesis, we investigated the effect of a PDE4 inhibitor on osteoclast formation in the presence of LPS. A specific PDE4 inhibitor, rolipram, increased LPS-induced osteoclast formation in cocultures. To verify that whether rolipram acts indirectly on osteoblasts, we investigated the TRANCE and COX-2 mRNA expression levels in osteoblasts. Treatment of rolipram increased the expression of TRANCE and COX-2 mRNA in osteoblasts stimulated by LPS. On the contrary, rolipram did not augment the number of osteoclasts differentiated from bone marrow cells by LPS. In conclusion, the stimulation of LPS-induced osteoclast formation by the PDE4 inhibitor are attributable to its indirect effect on osteoblasts, not to their direct effect on bone marrow-derived osteoclast precursors.

Electrophysiological and Behavioral Changes by Phosphodiesterase 4 Inhibitor in a Rat Model of Alcoholic Neuropathy

  • Han, Kyoung-Hee;Kim, Sung-Hoon;Jeong, In-Cheol;Lee, Young-Hee;Chang, Sei-Jin;Park, Bit-Na-Ri;Kim, Seok-Won
    • Journal of Korean Neurosurgical Society
    • /
    • 제52권1호
    • /
    • pp.32-36
    • /
    • 2012
  • Objective : Alcoholic neuropathy is characterized by allodynia (a discomfort evoked by normally innocuous stimuli), hyperalgesia (an exaggerated pain in response to painful stimuli) and spontaneous burning pain. The aim of the present study is to investigate the effect of rolipram, a phosphodiesterase 4 inhibitor, against alcohol-induced neuropathy in rats. Methods : Allodynia was induced by administering 35% v/v ethanol (10 g/kg; oral gavage) to Spraue-Dawley rats for 8 weeks. Rolipram and saline (vehicle) were administered intraperitoneally. Mechanical allodynia was measured by using von Frey filaments. Somatosensory evoked potential (SEP) was proposed as complementary measure to assess the integrity of nerve pathway. Results : The ethanol-induced mechanical allodynia began to manifest from 3 week, and then peaked within 1 week. Beginning from 3 week, latency significantly started to increased in control group. In rolipram treated rats, the shorter latency was sustained until 8 weeks (p<0.05). The mechanical allodynia, which began to manifest on the 3 weeks, intraperitoneal injections of rolipram sustained statistical difference until 8 weeks, the final week of the study (p<0.05). Conclusion : This study suggests that rolipram might alleviate mechanical allodynia induced by alcohol in rats, which clearly has clinical implication.

Usage and perceptions of phosphodiesterase type 5 inhibitors among the male partners of infertile couples

  • Song, Seung-Hun;Kim, Dong Suk;Shim, Sung Han;Lim, Jung Jin;Yang, Seung Choul
    • Clinical and Experimental Reproductive Medicine
    • /
    • 제43권1호
    • /
    • pp.26-30
    • /
    • 2016
  • Objective: We aimed to investigate the prevalence of erectile dysfunction (ED) and the usage of phosphodiesterase type 5 (PDE5) inhibitors for ED treatment in infertile couples. Methods: A total of 260 male partners in couples reporting infertility lasting at least 1 year were included in this study. In addition to an evaluation of infertility, all participants completed the International Index of Erectile Function (IIEF)-5 questionnaire to evaluate their sexual function. The participants were asked about their use of PDE5 inhibitors while trying to conceive during their partner's ovulatory period and about their concerns regarding the risks of PDE5 inhibitor use to any eventual pregnancy and/or the fetus. Results: Based on the IIEF-5 questionnaire, 41.5% of the participants (108/260) were classified as having mild ED (an IIEF-5 score of 17-21), while 10.4% of the participants (27/260) had greater than mild ED (an IIEF-5 score of 16 or less). The majority (74.2%, 193/260) of male partners of infertile couples had a negative perception of the safety of using a PDE5 inhibitor while trying to conceive. Only 11.1% of men (15/135) with ED in infertile couples had used a PDE5 inhibitor when attempting conception. Conclusion: ED was found to be common in the male partners of infertile couples, but the use of PDE5 inhibitors among these men was found to be very low. The majority of male partners were concerned about the risks of using PDE5 inhibitors when attempting to conceive. Appropriate counseling about this topic and treatment when necessary would likely be beneficial to infertile couples in which the male partner has ED.